Press "Enter" to skip to content

The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study

A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled “Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease” showed the potential of PDE5 Inhibitors in Alzheimer’s Disease (AD). The research finding confirms more than 10 years of pioneering research conducted by AriBio …

– 출처 :